Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.

Citation data:

The Prostate, ISSN: 1097-0045, Vol: 77, Issue: 6, Page: 584-596

Publication Year:
2017
Usage 16
Abstract Views 16
Captures 4
Readers 4
PMID:
28144973
DOI:
10.1002/pros.23298
Author(s):
Isharwal, Sumit, Modi, Shrey, Arora, Nivedita, Uhlrich, Charles, Giri, Bhuwan, Barlass, Usman, Soubra, Ayman, Chugh, Rohit, Dehm, Scott M, Dudeja, Vikas, Saluja, Ashok, Banerjee, Sulagna, Konety, Badrinath Show More Hide
Publisher(s):
Wiley-Blackwell
Tags:
Medicine
article description
With almost 30,000 deaths per year, prostate cancer is the second-leading cause of cancer-related death in men. Androgen Deprivation Therapy (ADT) has been the corner stone of prostate cancer treatment for decades. However, despite an initial response of prostate cancer to ADT, this eventually fails and the tumors recur, resulting in Castration Resistant Prostate Cancer (CRPC). Triptolide, a diterpene triepoxide, has been tested for its anti-tumor properties in a number of cancers for over a decade. Owing to its poor solubility in aqueous medium, its clinical application had been limited. To circumvent this problem, we have synthesized a water-soluble pro-drug of triptolide, Minnelide, that is currently being evaluated in a Phase 1 clinical trial against gastrointestinal tumors. In the current study, we assessed the therapeutic potential of Minnelide and its active compound triptolide against androgen dependent prostate cancer both in vitro as well as in vivo.

This article has 0 Wikipedia mention.